Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Joan Zimmer

Nurse Practitioner, Primary Care Spokane, WA Nurse Practitioner

NPI 1437343746 CMS profile 10970718

9103 N Division St, Spokane, WA 99218

Open in the dashboard

General payments

$11,671

470 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joan Zimmer of Spokane, WA is reported in the CMS Open Payments database as having received $11,671 across 470 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,752 73
2024 General $1,985 82
2023 General $2,212 102
2022 General $1,969 89
2021 General $3,754 124

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joan Zimmer
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Joan Zimmer were reported at $1,752. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Joan Zimmer Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $3,754 $137 $39–$445 $132
2022 $1,969 $139 $44–$421 $149
2023 $2,212 $163 $53–$481 $160
2024 $1,985 $176 $54–$511 $164
2025 $1,752 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,293 72 payments
  2. Janssen Pharmaceuticals, Inc $1,241 12 payments
  3. Amgen Inc. $931 41 payments
  4. AstraZeneca Pharmaceuticals LP $877 38 payments
  5. Lilly USA, LLC $594 31 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $594 19 payments
  7. Novo Nordisk Inc $416 21 payments
  8. Lundbeck LLC $369 17 payments
  9. Otsuka America Pharmaceutical, Inc. $369 17 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $364 9 payments
  11. Other $4,624 193 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,595 464 payments
  2. Consulting Fee $1,000 1 payment
  3. Education $77 5 payments
Products named General payments · program years 2021–2025
  1. SPRAVATO $1,224 11 payments
  2. TRINTELLIX $543 16 payments
  3. Repatha $464 21 payments
  4. UBRELVY $383 19 payments
  5. QULIPTA $380 23 payments
  6. Ozempic $372 18 payments
  7. REXULTI Psychiatry $369 17 payments
  8. RYBELSUS $347 17 payments
  9. BREZTRI $342 13 payments
  10. REXULTI Psychiatry $318 15 payments
  11. Other $9,159 419 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 106 drugs

Part D claims

4,484

Median for Nurse Practitioner: 389

Drug cost

$397,987

Median for Nurse Practitioner: $21,885

Branded share of claims

20.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 65 $70,804
Farxiga Dapagliflozin Propanediol Brand 65 $55,634
Eliquis Apixaban Brand 26 $31,843
Ozempic Semaglutide Brand 18 $27,422
Repatha Sureclick Evolocumab Brand 24 $20,981
Jardiance Empagliflozin Brand 13 $20,385
Vraylar Cariprazine Hcl Brand 13 $17,600
Trintellix Vortioxetine Hydrobromide Brand 25 $14,942
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 27 $14,889
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 21 $13,548

The 10 drugs with the highest cost, of 106 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$53,100

Medicare's payments for the services billed

Medicare patients

150

Average age 74

Services billed

1,119

114 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 41%
Osteoporosis 29%
Cancer 19%
Diabetes 18%
Depression 17%
Ischemic heart disease 13%
Chronic kidney disease 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $130
$130 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $92
  • Lilly USA, LLC $36
$128 13 —
Tymlos
  • Radius Health, Inc. $121
$121 — —
Auvelity
  • Axsome Therapeutics, Inc. $107
$107 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $75
  • Lundbeck LLC $18
$93 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

470 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record